Skip to main content

Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Places to Work in Rhode Island by Providence Business News

Company Earns Spot on Both Lists for Second Year in a Row

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that for the second year in a row the Boston Globe has named the Company among its annual Top Places to Work in Massachusetts in the medium-size employers category. In addition, Providence Business News included Rubius among the Best Places to Work in Rhode Island in the midsize employer category for the second year in a row. Rubius placed third on the list.

“We are thrilled and honored to be among the Top Places to Work both in Massachusetts and Rhode Island for the second year in a row,” said Theo Proukou, chief people officer at Rubius Therapeutics. “We have a culture unlike anywhere else, one that is uniquely tied to our values and emanates through the work that we do for patients every single day. These awards are only made possible because of our employees and their commitment to our culture and mission to create life-changing cellular therapies for patients who need them.”

Rubius is built on the core values of integrity, inventiveness, inclusivity, courage and urgency and prides itself on consistently living these values across every function at every level. The Company’s benefit offerings help employees thrive, both at work and at home, taking each individual’s physical, mental and financial well-being into consideration. Rubius is headquartered in Cambridge, Massachusetts, and its manufacturing facility is in Smithfield, Rhode Island. For more information on Rubius’ culture and benefits, please visit rubiustx.com/careers.

The rankings in the Boston Globe’s Top Places to Work in Massachusetts list are based on a survey collected by Energage, an employee research and consulting firm. Employers around the state were invited to have their employees take an anonymous survey covering factors from leadership to benefits to feeling appreciated.

The Providence Business News’ Best Places to Work list is a statewide survey and awards program designed to identify, recognize and honor the best places of employment in Rhode Island, benefiting the state’s economy, workforce and businesses. The list is made up of 72 total companies, broken down by size of the employer. The companies were judged based on human resource policies and confidential surveys of employees compiled by Best Companies Group.

About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:
Media 
Marissa Hanify
Director, Corporate Communications
marissa.hanify@rubiustx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.